These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30209407)

  • 1. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.
    Curtin K; Fleckenstein AE; Keeshin BR; Yurgelun-Todd DA; Renshaw PF; Smith KR; Hanson GR
    Neuropsychopharmacology; 2018 Dec; 43(13):2548-2555. PubMed ID: 30209407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
    Walitza S; Melfsen S; Herhaus G; Scheuerpflug P; Warnke A; Müller T; Lange KW; Gerlach M
    J Neural Transm Suppl; 2007; (72):311-5. PubMed ID: 17982908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
    Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
    Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder.
    Sobel LJ; Bansal R; Maia TV; Sanchez J; Mazzone L; Durkin K; Liu J; Hao X; Ivanov I; Miller A; Greenhill LL; Peterson BS
    Am J Psychiatry; 2010 Aug; 167(8):977-86. PubMed ID: 20595414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study.
    Groenman AP; Oosterlaan J; Rommelse N; Franke B; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Addiction; 2013 Aug; 108(8):1503-11. PubMed ID: 23506232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood Attention-Deficit/Hyperactivity Disorder, Sex, and Obesity: A Longitudinal Population-Based Study.
    Aguirre Castaneda RL; Kumar S; Voigt RG; Leibson CL; Barbaresi WJ; Weaver AL; Killian JM; Katusic SK
    Mayo Clin Proc; 2016 Mar; 91(3):352-61. PubMed ID: 26853710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders.
    Peterson BS; Leckman JF; Tucker D; Scahill L; Staib L; Zhang H; King R; Cohen DJ; Gore JC; Lombroso P
    Arch Gen Psychiatry; 2000 Apr; 57(4):364-72. PubMed ID: 10768698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Perinatal and Childhood Ischemic Stroke With Attention-Deficit/Hyperactivity Disorder.
    Bolk J; Simatou E; Söderling J; Thorell LB; Persson M; Sundelin H
    JAMA Netw Open; 2022 Apr; 5(4):e228884. PubMed ID: 35471571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
    Liang SH; Yang YH; Kuo TY; Liao YT; Lin TC; Lee Y; McIntyre RS; Kelsen BA; Wang TN; Chen VC
    Res Dev Disabil; 2018 Jan; 72():96-105. PubMed ID: 29121517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Population-Based Imaging Genetics Study of Inattention/Hyperactivity: Basal Ganglia and Genetic Pathways.
    Mous SE; Hammerschlag AR; Polderman TJ; Verhulst FC; Tiemeier H; van der Lugt A; Jaddoe VW; Hofman A; White T; Posthuma D
    J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):745-52. PubMed ID: 26299296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
    Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
    Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do prescription stimulants increase risk of Parkinson's disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study.
    Kindt HM; Tuan WJ; Bone CW
    Fam Pract; 2024 Aug; 41(4):605-609. PubMed ID: 36593727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
    Van Brunt DL; Johnston JA; Ye W; Pohl GM; O'Hara NN
    J Manag Care Pharm; 2006 Apr; 12(3):230-8. PubMed ID: 16623607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.